- Home
- PRQR vs ENGN Comparison
PRQR vs ENGN Comparison
Compare PRQR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- ENGN
- Stock Information
- Founded
- PRQR 2012
- ENGN 1999
- Country
- PRQR Netherlands
- ENGN Canada
- Employees
- PRQR N/A
- ENGN N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- PRQR Health Care
- ENGN
- Exchange
- PRQR Nasdaq
- ENGN Nasdaq
- Market Cap
- PRQR 179.1M
- ENGN 204.3M
- IPO Year
- PRQR 2014
- ENGN N/A
- Fundamental
- Price
- PRQR $2.13
- ENGN $3.74
- Analyst Decision
- PRQR Strong Buy
- ENGN Buy
- Analyst Count
- PRQR 8
- ENGN 7
- Target Price
- PRQR $8.88
- ENGN $23.29
- AVG Volume (30 Days)
- PRQR 362.3K
- ENGN 97.3K
- Earning Date
- PRQR 08-07-2025
- ENGN 06-12-2025
- Dividend Yield
- PRQR N/A
- ENGN N/A
- EPS Growth
- PRQR N/A
- ENGN N/A
- EPS
- PRQR N/A
- ENGN N/A
- Revenue
- PRQR $21,212,711.00
- ENGN N/A
- Revenue This Year
- PRQR N/A
- ENGN N/A
- Revenue Next Year
- PRQR N/A
- ENGN N/A
- P/E Ratio
- PRQR N/A
- ENGN N/A
- Revenue Growth
- PRQR 85.91
- ENGN N/A
- 52 Week Low
- PRQR $1.07
- ENGN $2.65
- 52 Week High
- PRQR $4.62
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- PRQR 64.73
- ENGN 56.20
- Support Level
- PRQR $1.89
- ENGN $2.95
- Resistance Level
- PRQR $2.54
- ENGN $3.44
- Average True Range (ATR)
- PRQR 0.14
- ENGN 0.27
- MACD
- PRQR 0.01
- ENGN 0.07
- Stochastic Oscillator
- PRQR 43.06
- ENGN 77.78
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.